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Abstract
Somatic cell nuclear transfer (SCNT) has been proved capable of reprogramming various differentiated somatic cells into
pluripotent stem cells. Recently, induced pluripotent stem cells (iPS) have been successfully derived from mouse and human
somaticcellsbytheover-expressionof a combinationof transcriptionfactors. However, the molecular mechanismsunderlying
the reprogramming mediated by either the SCNT or iPS approach are poorly understood. Increasing evidence indicates that
many tumor pathways play roles in the derivation of iPS cells. Embryonal carcinoma (EC) cells have the characteristics of both
stem cells and cancer cells and thus they might be the better candidates for elucidating the details of the reprogramming
process. Although previous studies indicatethat ECcellscannot be reprogrammedinto real pluripotent stem cells,the reasons
forthisremainunclear.Here,nucleifrommouseECcells(P19)weretransplantedintoenucleatedoocytesandpluripotentstem
cells (P19 NTES cells) were subsequently established. Interestingly, P19 NTES cells prolonged the development of tetraploid
aggregated embryos compared to EC cells alone. More importantly, we found that the expression recovery of the imprinted
H19 gene was dependent on the methylation state in the differential methylation region (DMR). The induction of Nanog
expression, however, was independent of the promoter region DNA methylation state in P19 NTES cells. A whole-genome
transcriptome analysis further demonstrated thatP19 NTES cells were indeed the intermediates between P19 cells and ES cells
and many interesting genes were uncovered that may be responsible for the failed reprogramming of P19 cells. To our
knowledge, for the first time, we linked incomplete reprogramming to the improved pluripotency of EC cell-derived
pluripotent stem cells. The candidate genes we discovered may be useful not only for understanding the mechanisms of
reprogramming, but also for deciphering the transition between tumorigenesis and pluripotency.
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Introduction
Various differentiated somatic cells can be reprogrammed into a
totipotent, or at least pluripotent state by somatic cell nuclear
transfer (SCNT), which includes fetus-derived epithelial cell lines
[1], cumulus cells [2], mature B and T lymphocytes [3], olfactory
sensory neurons [4,5] and natural killer T cells [6]. This
reprogramming process requires the reversal of epigenetic
modifications, such as DNA methylation, histone modifications,
and the condensation state of chromatin [7]. Recently, induced
pluripotent stem (iPS) cells were generated by the forced
expression of four transcription factors in mouse fibroblasts, and
the derived iPS cells are similar to ES cells [8]. However, the
detailed mechanisms underlying these complicated reprogram-
ming events are not well understood.
Epigenetic modifications play important roles during the
development of embryos and the initiation of disease. The
definition of cell fate always coincides with changes in its
epigenetic modifications, such as DNA methylation and histone
modifications. Aberrant epigenetic modifications could result in
many kinds of diseases, such as cancer [9]. For instance, it is well
known that the promoter regions of many important tumor
suppressor-genes are always hypermethylated, which inactivates
the supervisory roles of tumor suppressor genes, thus resulting in
the neoplasia [10]. During the reprogramming process mediated
by SCNT, genetic alternations cannot be corrected, whereas the
epigenetic modifications can indeed be reset.
Embryonal carcinoma (EC) cells, derived from teratocarcino-
mas, are capable of unlimited self-renewal and can differentiate
into several kinds of somatic cells. The isolation of EC cells also
provides us with a preliminary framework for embryonic stem cells
[11]. Thus, EC cells are widely used as the in vitro models for
dissecting several fundamental questions related to development
and pluripotency [12]. Moreover, the discovery of EC cells
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10320demonstrated the existence of the so-called ‘‘cancer stem cells’’ for
the first time, predating the current interest in these by several
decades. Although EC cells still have similar characteristics to
other cancer cells, such as the genetic mutations, they differ from
other kinds of cancer cells in the developmental potential, as
assessed by the blastocyst injection assay [13].
Previous studies have indicated that some tumor cells are able to
direct the development of early cloned embryos, producing
morphologically normal blastocysts that give rise to NTES cell
lines, but the cloned embryos are not able to develop into live pups
after their transfer into the uterus [14,15,16]. The failed
reprogramming of tumor cells may be due to characteristics of
the donor cells, such as the profound genetic changes or the
differentiation states of these cells. Accumulated evidence implies
that cancer cells may have an inseparable connection with induced
pluripotent cells [8,17,18]. Considering the special status of EC
cells, which have the dual identities of both cancer cells and
multipotent cells, we have designed our experiments relying on EC
cells. The reprogramming of EC cells may provide an excellent
model for understanding the maintenance of tumorigenic potential
and pluripotency.
In the present study, we attempted to answer two questions by
reprogramming P19 EC cells through SCNT: (I) Can EC cells be
reprogrammed and become pluripotent, and to what extent can
they be reprogrammed? (II) What molecular events occur during
the reprogramming of EC cells?
Results
1. The development of cloned embryos reconstructed
with P19 cells and the establishment of P19 cell-derived
pluripotent stem cells
In this study, two tumor cell lines (N2a and P19) with different
development potentials were chosen as the donors for the nuclear
transplantation. Compared to the N2a cell line, the P19 cell line
was highly tumorigenic and in a low differentiation state,
characteristics that were verified by the subcutaneous injection
into immunodeficient mice (data not shown). P19 cells also always
adhered to the culture dish and showed a typical morphology of
cancer cells when cultured in vitro (Figure 1A).
Nucleifrom thetwotumorcell lineswereinjected intoenucleated
B6D2F1 oocytes and the reconstructed oocytes were activated and
cultured to evaluate their in vitro developmental capacity. We were
unable to obtain cloned blastocysts from 53 reconstructed oocytes
containing the nuclei of N2a cells, but we succeeded in producing
171 cloned blastocysts from 628 oocytes after the transfer of nuclei
from P19 cells. The development of P19 cell-derived cloned
embryos resembled the embryos derived from cumulus cells, which
always acted as the control for the routine nuclear transfer assay
(Figure 1B, C, D, E). The proportion of cleaved oocytes that
reached the blastocyst stage was nearly 30% (Table 1).
Because blastocysts reconstructed with P19 cells had a higher
developmental rate, we were very interested in whether these
Figure 1. The reprogramming of EC cells and establishment of P19 NTES cell lines. (A) P19 cells cultured in vitro. (B) Two-cell stage cloned
embryos of P19 cells. (C) Four-cell stage cloned embryos of P19 cells. (D) Eight-cell or morula stage cloned embryos of P19 cells. (E) Reconstructed
blastocyst derived from P19 cells. (F) Outgrowth generated from in vitro cultured cloned blastocyst of P19 cells. (G) P19 NTES1 cell line at Passage 10.
(H) P19 NTES7 cell line at Passage 11. (I) Karyotype analysis of P19 cells. The X-axis represents different chromosome number; the Y-axis represents the
percentage of cells with different chromosome number. (J) Karyotype analysis of P19 NTES cell lines. The X-axis represents the serial number of P19
NTES cell line; the Y-axis represents the normal karyotype percentage of each cell line. (K) A typical karyotype of P19 NTES7.
doi:10.1371/journal.pone.0010320.g001
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embryos. Therefore, cloned blastocysts derived from P19 cells
were transferred back into the uteri of pseudo-pregnant mice, but
we failed to get full-term pups. Then we tried to obtain cloned
pups through the ‘‘two-step’’ cloning method, which was efficient
in overcoming the underlying handicaps that resulted from the
direct cloning [3,4]. First, seven NTES cell lines were established
from 21 cloned blastocysts derived from P19 cells with a rate of
about 33.3%, which was comparable to the rate of cell lines
derived from fertilized embryos (data not shown). These NTES
cells from the P19 cells all had the typical morphology of normal
ES cells and could be passaged in vitro long-term (Figure 1F, G, H).
As tumor cells always had karyotype problems, we eliminated the
impact resulting from abnormal karyotypes by selecting normal ES
cell lines. As seen from Figure 1I, the karyotypes of the P19 cells
were relatively normal, 78.7% of which contained 40 chromo-
somes. Among the P19 NTES cells, however, only P19
NTES7 cells showed relatively normal karyotypes (73.3%) and
this line was thus selected for subsequent experiments
(Figure 1J, K).
2. Pluripotent P19 NTES cells dramatically prolong the
development of tetraploid aggregated embryos
P19 NTES cells maintained the typical morphology of normal
murine ES cells when cultured in vitro long-term. After this period
of culturing, we performed teratoma formation and tetraploid
blastocyst aggregation assays to verify their pluripotency. After
being subcutaneously injected into SCID mice for three to four
weeks, P19 NTES cells could form teratomas with a high
frequency. The histology of the resulting tumors from P19 NTES
cells exhibited differentiation into neural and glial cells (Figure 2A),
gland and column-like epithelia (Figure 2B), and skeletal muscle
(Figure 2C). Moreover, the expression of pluripotent genes, such as
Zfp42, Nanog, Sox2 and Pou5f1, were also observed in P19 NTES
cells, although P19 cells also had a high background expression of
these pluripotent markers (Figure 2D).
The EC cells joined in the formation of somatic tissues after they
were injected into blastocysts [13]. Therefore, the detection of
three germ layers in the teratoma tissues could just reflect the in
vivo differentiation potential of P19 NTES cells, not their real
pluripotency. It was also unknown whether pluripotent stem cells
Table 1. In vitro development of embryos after nuclear transfer of N2a cells, P19 cells, and cumulus cells (CCs).
Cell Type No. of Oocytes No. of 2-Cell (%) No. of 4-Cell (%) No. of Morula (%) No. of Blastocyst (%)
N2a 53 33 (60.7612.2)
a 9 (16.466.8)
a 0( 0 )
a 0 (0)
a
P19 361 299 (83.662.1)
b 191 (53.461.6)
b 129 (36.161.5)
b 95 (29.761.6)
b
CCs 452 412 (91.262.7)
b 259 (57.466.5)
b 173 (38.4611.6)
b 117 (26.065.4)
b
a, b, c: These values differ significantly from one another (P,0.05).
doi:10.1371/journal.pone.0010320.t001
Figure 2. Pluripotency verifications of P19 NTES cells. Teratoma formation, RT-PCR and tetraploid aggregated assays were used to evaluate
the pluripotency of P19 NTES cells from different aspects. (A), (B), (C) HE staining results of the paraffin embedded sections of teratoma derived from
P19 NTES7. As shown in A-C, neuron tube and glia cells, gland, and column-like epithelium and skeleton muscle, which represent the three germ
layers, respectively, could be observed in teratoma tissues. (D) The expression of pluripotent genes of P19 and P19 NTES cells as determined by RT-
PCR. (E) The uterus and the dead tetraploid embryos of P19 cells at E8.5. (F) The uterus and the dead tetraploid embryos of P19 NTES7 at E8.5. (G) The
uterus transplanted with tetraploid embryos derived from P19 NTES1 at E8.5.
doi:10.1371/journal.pone.0010320.g002
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potential and maintain the full-term development of the tetraploid
chimera, which was the stringent standard for pluripotency.
Therefore, tetraploid blastocyst aggregation assays were per-
formed with P19 cells and P19 NTES cells separately. Among the
121 blastocysts injected with P19 cells, only four placentas under
absorption were observed at embryonic day (E) 8.5, which was
consistent with the results of previous studies, and no live fetuses
could be isolated from the absorbing tissues after C-section
(Figure 2E and Table 2). In contrast to P19 cells, P19 NTES7
could prolong the development of tetraploid aggregated embryos
dramatically. As shown in Figure 2F and Table 2, tetraploid
aggregated embryos derived from P19 NTES7 always had bigger
placentas than those of P19 cells and the implantation rate was
very high, which was a direct indication of increased pluripotency.
Although most of these implanted tetraploid complementary
embryos derived from P19 NTES7 died before E8.5, we were able
to obtain six live E8.5 fetuses of P19 NTES7 from the pseudo-
pregnant mice via C-section (Table 2). In contrast to P19 NTES7
cells, P19 NTES1 cells failed to maintain the early development of
tetraploid aggregated embryos beyond E8.5 (Figure 2G and
Table 2). Therefore, although P19 NTES7 also failed to maintain
the full-term development of tetraploid aggregated embryos, it did
have an increased pluripotency compared to its progenitor P19
cells.
These data indicated that P19 NTES cells had an increased
pluripotency compared to their progenitor cells and the improved
pluripotency could extend the development of tetraploid aggre-
gated embryos dramatically. However, not every P19 NTES cell
line had the similar improved pluripotency of P19 NTES7, with
P19 NTES1 as the typical example.
3. The results of molecular analyses indicate that P19
NTES cells are intermediate between EC cells and ES cells
Because P19 NTES cells showed an improved pluripotency as
compared with progenitor cells, we hypothesized that undiscov-
ered molecular events lead to this cell fate transition. We thus
decided to characterize this phenomenon by thoroughly analyzing
the molecular characteristics of P19 NTES cells. We used real-
time PCR and microarrays to generate a global view of the
transcriptional change during the reprogramming process of P19
cells. First, we analyzed the expression of many cancer or
pluripotency-related genes in P19 NTES7 cells with several
specific cell lines as controls. These cell lines included the normal
ES cells (R1), which are the gold standard of true pluripotency,
NTES cells derived from Sertoli cells (S16), iPS cells generated
from fibroblasts (iPS) and mouse embryonic fibroblasts (MEF). As
shown in Figure 3A-F, we classified these genes into three groups.
The first group included the genes that could be induced during
the reprogramming process of P19 cells by NT, with Nanog as the
representative gene. The second group comprised the genes that
could not be induced to the expression level of normal ES cells,
with Trp53 as the example. The third group contained the genes
with no expression change during this process, such as Pou5f1 and
Sox2. Thus, we had direct evidence supporting our hypothesis that
P19 NTES7 had a unique molecular code, which was worthy of a
deeper analysis.
To test this hypothesis, we used microarray for analyzing the
transcriptome of P19 NTES cells to help us understand the
improved pluripotency detected (Accession number: GSE18691).
The microarray results were first displayed as scatter plots, in
which the differentially expressed probe sets were marked by red
and green dots, while the unchanged probe sets were marked by
blue dots. As shown in Figure 4A, P19 cells had a distinct
expression pattern compared to R1 ES cells, and these
differentially expressed probe sets represented the difference
between EC cells and ES cells. In contrast to the distinct
expression pattern in the P19 versus R1 group, the P19 NTES7
versus P19 group and the P19 NTES7 versus R1 group had fewer
differentially expressed probe sets. In order to reduce the noise in
our analysis, we increased the threshold level (fold change.2, one-
way analysis of variance (ANOVA) p-value,0.01). Among the
probe sets covered in the GeneChipH Gene 1.0 ST Array System
for the mouse genome, we found 1641 differentially expressed
probe sets between P19 cells and R1 representing 1514 genes
(Dataset S1). The sorted genes included several important genes,
such as BMP4, Fbxo15, Dppa5a, Esrrb, Trp53, Nanog, Klf4, H19,
Tbx3 and c-Myc. Nearly all of these genes met the more stringent
selection standard of significance (fold change.5, one-way
ANOVA p-value,0.001), with c-Myc as an exception for its
special role in both tumorigenesis and reprogramming. Interest-
ingly, these genes always related to pluripotency (BMP4, Fbxo15,
Dppa5a, Nanog) and tumorigenesis (Trp53, Klf4, H19, c-Myc). The
expression patterns of these genes were verified by real-time PCR
with P19 cells as the reference. As shown in Figure 4B and Dataset
S2, the results of the quantitative PCR corresponded well to the
microarray results (Max fold change.2.5, p-value,0.01) (Table 3).
Among these genes, Nanog and H19 in P19 NTES7 were the
outstanding ones because they were successfully induced to the
normal expression level, while Fbxo15, Dppa5a, Esrrb, Klf4 and c-
Myc were only induced to an intermediate level. In striking
contrast, BMP4, Trp53 and Tbx3 still maintained the expression
patterns of EC cells, without any induction trend. As we know,
these genes are all involved in critical signaling pathways, and the
dysfunction of any of these genes will lead to tumorigeneis.
Altogether, these results suggested that P19 NTES7 cells were
really the intermediate between P19 cells and R1 cells and this
intermediate had the identities of partial pluripotent stem cells, not
only at the level of development potential, but also at the
molecular level. Taking this into consideration, we decided to
further explore the hierarchy among them.
Next, an unsupervised hierarchical clustering analysis was
performed to assess the similarities in single gene expression
profiles in an unbiased way among the P19, P19 NTES7 and R1
cells and all the differentially expressed genes were covered
(Figure 4C). In the resulting sample tree, P19 cells and R1 cells
Table 2. The development of tetraploid mice derived from P19, P19NTES7 and P19NTES1 cells.
Cell type Injected blastocyst Implantation site Embryos Arrested before E8.5 Live pups at E8.5 Full term pups
P19 121 4 4 0 0
P19 NTES7 459 231 225 6 0
P19 NTES1 156 0 0 0 0
doi:10.1371/journal.pone.0010320.t002
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them. This may account for the intrinsic difference between
cancer cells and ES cells. However, P19 NTES7 showed a
different schema when compared to either P19 cells or R1. In the
top and bottom of the resulting sample tree, P19 NTES7 clustered
with R1 cells, while in the middle region, P19 NTES7 clustered
with P19 cells. Hierarchical clustering revealed the intermediate
state of P19 NTES7 at the gene expression level.
A principal components analysis (PCA), an exploratory
multivariate statistical technique always used to simplify complex
data sets, was used to evaluate the microarray data. Using this
approach, similar samples should be close in distance [19]. As seen
from Figure 4D, the three replicates of each cell line were all the
closest in the PCA and the separation among the three kinds of cell
lines was clear. Therefore, the PCA analysis indicated that the
repeatability of microarray data was reliable and the main variable
component came from the origin of every cell line.
In summary, these experiments demonstrated that P19 NTES
cells had unique molecular characteristics and they were indeed
the intermediates between EC cells and ES cells. The gain of
function of many pivotal genes in P19 NTES cells coming from
partial reprogramming might account for the extended develop-
ment of tetraploid aggregated embryos observed in the earlier
experiments.
4. Gene Ontology and pathways enrichment of
differentially expressed genes among P19 cells, P19 NTES
cells and normal ES cells
In order to understand functions of differentially expressed
genes among the P19, P19 NTES7 and R1 cells, we pursued an
alternative comparative approach and a gene ontology (GO)
analysis was used to identify categories within which genes differed
significantly in these cells. First, we screened the differentially
expressed genes from P19 versus R1 and this set of genes was
named as GeneSet A or A (Dataset S1) (fold change .2, one-way
ANOVA p-value ,0.01). Then we further sub-classified GeneSet
A into two sub-groups. The first was named as GeneSet B or B
(Dataset S3), and genes in this set met the significance standard for
GeneSet A and the one for P19 versus P19 NTES7 (fold change .
2, one-way ANOVA p-value ,0.01). Genes in GeneSet C or C
(Dataset S4) met the significance standard for GeneSet A and the
one for P19 NTES7 versus R1 (fold change .2, one-way ANOVA
p-value ,0.01). Under this stringent classification standard,
GeneSet A was regarded as the molecular differences between
Figure 3. The comparison of P19 NTES cells to normal ES cells, NTES cells, iPS cells and MEF. Quantitative PCR was used to assess the
difference among these cells at the level of mRNA by analyzing several important genes. (A), (B) Nanog and c-Myc are representative of genes that
could be induced in P19 NTES cells successfully. (C), (D) Trp53 and Klf4 are representative of genes that could not be induced in P19 NTES cells. (E), (F)
Pou5f1 and Sox2 are genes that did not change during the process of EC reprogramming. Error bars depict standard deviation. p-value,0.01.
doi:10.1371/journal.pone.0010320.g003
Reprogramming of EC Cells
PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10320EC cells and normal ES cells, GeneSet B represented the genes
that were successfully reprogrammed during EC cells reprogram-
ming, and GeneSet C represented the genes which have not been
successfully reprogrammed.
The reliability of this classification was confirmed by the
overlapping results in Figure 4E and Dataset S5. Among the 1514
genes included in GeneSet A, GeneSet B contained 306 genes and
GeneSet C contained 635 genes. GeneSet B and GeneSet C were
also well separated with only 42 overlapping genes. Therefore,
this sub-classification standard could provide us with more
reliable information for furtheranalyzing the functionsofthese genes.
Next, GO analysis was used to identify the functional categories
overrepresented in the cluster genes from GeneSet B and GeneSet C.
As shown in Figure 5A-C, the functional categories identified from
the two groups of genes were very similar and the enriched categories
included several biological processes, such as the developmental
process, metabolic process, transcription, transport and cell differen-
tiation. Intriguingly, these biological processes corresponded to
several molecular functions, for instance, protein binding, catalytic
activity and ion binding. When we reduced the scope by comparing
the functional categories covered in GeneSet B and C, we found
that the protein binding activity was the only different one
Figure 4. Molecular characteristics of P19 NTES cells. Scatter plot analysis was performed to compare the global gene expression profiles
among different groups; hierarchical clustering and overlapping were further carried out to sort and analyze the differentially expressed genes. (A)
Scatter plot analysis of the differentially expressed probe sets among P19 cells, P19 NTES cells and R1. Blue dots represent the unchanged probe sets;
red dots represent the up-regulated probe sets; green dots represent the down-regulated probe sets. (B) Verification of the expression of several
important genes undergoing dramatic changes by quantitative PCR. Error bars depict standard deviation. * p-value ,0.05; ** p-value ,0.01;
*** p-value ,0.001 (C) Unsupervised hierarchical clustering of averaged global transcriptional profiles obtained from P19 cells, P19 NTES cells and R1.
(D) PCA. (E) Overlapping analysis of GeneSets A, B, and C.
doi:10.1371/journal.pone.0010320.g004
Table 3. Transcriptional profiles of specific genes in the Microarray Database.
Gene P19 mean P19NTES7 mean R1 mean Fold Change (max) P-value Gene Description
BMP4 14.2228 12.7877 113.1357 8.847228 3.77E-07 Bone morphogenetic protein 4
Fbxo15 13.4023 66.3999 304.1208 22.691687 1.13E-06 F-box protein 15
Dppa5a 19.5185 125.3853 2238.42 114.681958 5.33E-07 Developmental pluripotency
associated 5A
Esrrb 9.2619 32.4116 229.8209 24.813580 1.96E-08 Estrogen related receptor, beta
P53 11.393 11.1797 531.9999 47.586241 7.53E-12 Transformation related protein
53
Nanog 177.6313 626.9135 913.3968 5.142094 8.23E-07 Nanog homeobox
Klf4 13.0388 41.4887 125.5365 9.627918 5.58E-08 Kruppel-like factor 4 (gut)
H19 14.8403 172.4851 108.9784 11.622750 2.11E-05 H19 fetal liver mRNA
Tbx3 12.4563 19.7289 65.3785 5.248629 3.47E-05 T-box 3
c-Myc 61.274 86.9802 157.5109 2.570599 0.0029226 Myelocytomatosis oncogene
doi:10.1371/journal.pone.0010320.t003
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supporting information, Dataset S6, Dataset S7, and Dataset S8.
Overall, our data indicated that GeneSet B and GeneSet C
converged on similar functional categories and the enriched activities
may be prevalent in the transition of EC cells into ES cells.
A pathways enrichment analysis was then performed to refine
the differentially expressed genes into specific signaling pathways
during the reprogramming process. As shown in Dataset S9,
GeneSet A covered six conventional signaling pathways,
including the MAPK, focal adhesion, P53, ECM-receptor
interaction, tight junction and VEGF signaling pathways, and
these pathways needed to be recovered when the EC cells were
reprogrammed into pluripotent stem cells (p-value ,0.05).
Regarding GeneSet B and C, we found the pathways covered
in GeneSet B were reduced dramatically and only contained the
MAPK, ECM-receptor interaction and focal adhesion signaling
pathways. Nevertheless, GeneSet C could map to the tight
junction, focal adhesion, VEGF and p53 signaling pathways,
which was in contrast to GeneSet B (Dataset S10, Dataset S11)
(p-value ,0.05). The recovered genes mainly fell into the MAPK,
ECM-receptor interaction and focal adhesion signaling pathways.
For instance, c-Myc, the downstream member of the MAPK
pathway, was induced partially while the focal adhesion signal
pathway could only be repaired partly. Most importance of all,
the P53 pathway failed to be recovered, with many critical genes
inactive, such as Trp53, Gadd45 and Cdkn1a (Figure S1, Figure
S2). The role of P53 was complex for its non-protecting function
in germ cell tumors and negative expression in germ cells and
sertoli cells [20,21]. Therefore, P19-derived pluripotent stem cells
still bear the similar attributes of cancer cells and a P53
independent mechanism may exist for protection. In brief, the
pathways enrichment results suggested that the reprogramming of
EC cells through NT could repair the MAPK, ECM-receptor
interaction and focal adhesion signaling pathways, at least
partially, but not the P53 pathway.
5. The expression recovery of H19 is dependent on
methylation in the differential methylation region (DMR),
while the induction of Nanog is independent of the
promoter region methylation
As showed in the data thus far, P19 NTES cells resulted from an
incomplete reprogramming, with many genes fully induced, such
as H19 and Nanog, and many genes partially induced, such as
Fbxo15, Dppa5a and Esrrb. However, the mechanisms underlying
the induction of these genes were unclear, especially for the
representatives of the fully induced genes, H19 and Nanog.
Combined with the GO results, which indicated that GeneSet B
always took part in the protein binding, we reasoned that specific
epigenetic transformations may have been involved in the
reprogramming of the EC cells.
In order to test this hypothesis, we analyzed the DNA
methylation changes during the induction of H19 and Nanog using
the bisulfite genomic sequencing method. Moreover, western blot
was also performed to analyze the expression status of Nanog
during the process of reprogramming, but not H19 due to its
protein non-coding property [22]. As shown in Table 3 and
Figure 6A, the expression of H19 could be recovered to a normal
level. The expression of the other imprinted gene, Peg3, had no
change, which has been verified by the microarray and real-time
PCR (Figure 6B). Next, the DMRs of H19 and Peg3 were analyzed
for their DNA methylation patterns. Interestingly, the methylation
in the DMR of H19 in P19 cells was very high (135/150), while the
levels in P19 NTES7 and R1 were within the normal range (55/
150, 71/135) (Figure 6C, D, E, F). In contrast to H19, there was
no change of the DNA methylation profiles of Peg3 among these
cell lines and it acted as a better control for H19 (Figure 6G, H, I,
J). The observed hypermethylation of P19 cells corresponded to
the repression of H19 and the induction of H19 was dependent on
the methylation in the DMR.
Similar to H19, the mRNA level of Nanog was also induced to a
relatively normal level in P19 NTES cells (Table 3 and Figure 3A).
Figure 5. Functional annotation of the differentially expressed genes during the incomplete reprogramming of P19 cells. Gene
Oncology analysis was performed to identify functional categories overrepresented in the cluster of genes of GeneSet B and C. (A) Gene Oncology
analysis of Group B and Group C according to biological process. (B) Gene Oncology analysis of Group B and Group C according to cell component.
(C) Gene Oncology analysis of Group B and Group C according to molecular function. The blue column represents Group B; the red column
represents Group C. The X-axis represents the percentage of each sub-category in this category. The Y-axis represents a detailed description of the
roles of each sub-category. p-value,0.05.
doi:10.1371/journal.pone.0010320.g005
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time PCR data (Figure 7B). We also analyzed the DNA
methylation profiles in the promoter region of Nanog, with Pou5f1
as the control (Figure 7A, G). As shown in Figure 7C, D, E, F, the
methylation of Nanog in P19, P19 NTES7 and R1 were all very low
(9/132; 7/132; 7/132) while the methylation level in MEF was
very high (90/132). Nanog was one of the important factors in the
generation of iPS cells and it also played major roles in
maintaining pluripotency. The regulation of Nanog always relied
on the methylation state in the promoter region, with hypomethy-
lation resulting in activation and hypermethylation resulting in
silence. Therefore, our results provided direct evidence for the
existence of a specific regulatory circuit in controlling the
expression of Nanog in EC cells and the recovery of Nanog was
the remarkable indicator of the improved pluripotency in P19
NTES cells. When we analyzed the methylation patterns of Pou5f1,
we found that the unchanged expression of Pou5f1 correlated with
the ubiquitous hypomethylation of the promoter region in P19,
P19 NTES7 and R1, with MEF as the negative control (Table 3
and Figure 7I, G, K, L). The DNA sequencing results were further
confirmed by restriction enzyme digestion assays (Figure 7H).
In summary, the induction of H19 during the partial
reprogramming of EC cells was in a DMR methylation-dependent
pattern while the induction of Nanog was independent of the
promoter region methylation.
Discussion
In this study, we addressed two questions that remain regarding
the reprogramming of embryonal carcinoma cells by using a ‘‘two-
Figure 6. The expression analysis of H19, Peg3 and DNA methylation analysis of their specific DMRs. In order to understand the
relationship between the induction of H19 and DNA methylation of its DMR, bisulfite genomic sequencing was performed among P19, P19 NTES7
and R1, with Peg3 as control. (A), (B) The expression analysis of H19 and Peg3 determined by quantitative PCR. Error bars depict standard deviation.
** p-value,0.01; *** p-value,0.001 (C) The CpG islands contained in DMR of H19 are shown schematically. (D), (E), (F) The bisulfite genomic
sequencing results of H19 in P19, P19 NTES7 and R1 are shown. (G) The CpG islands contained in DMR of Peg3 are shown schematically. (H), (I), (J) The
bisulfite genomic sequencing results of Peg3 in P19, P19 NTES7 and R1 are shown schematically. The black circle represents the methylated CpG
island, the white circle represents the unmethylated CpG island.
doi:10.1371/journal.pone.0010320.g006
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PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10320Figure 7. The expression analysis of Nanog, Pou5f1 and DNA methylation analysis of their specific promoter regions. In order to
investigate the induction mechanisms of Nanog, bisulfite genomic sequencing was performed to analyze DNA methylation changes of its promoter
region, which is the well-known regulatory element of Nanog, among P19, P19 NTES7 and R1, with Pou5f1 as control. (A) The CpG islands in the
promoter region of Nanog are shown schematically. (B) The expression analysis of Nanog in P19, P19 NTES7, R1 and P19 NTES1 determined by
western blot. From left to right, P19, P19 NTES7, R1 and P19 NTES1 are listed sequentially. (C), (D), (E), (F) The bisulfite genomic sequencing results of
Nanog in P19, P19 NTES7, R1 and MEF are shown schematically. (G) The CpG islands in the promoter region of Pou5f1 are shown schematically; and
the arrows show the recognition sites of Taq I. (H) The gel electrophoresis results of Pou5f1 digested by Taq I. (+): digested and (2): undigested. From
left to right, P19, P19 NTES7, R1 and MEF are listed sequentially. The black circle represents the methylated CpG island; the white circle represents the
unmethylated CpG island.
doi:10.1371/journal.pone.0010320.g007
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cells have an improved pluripotency compared to their progenitor
cells, as we observed in the tetraploid aggregated embryos assays.
The gain of function of several pluripotent genes identified by
high-throughput methods may account for this phenomenon.
However, the reprogramming of EC cells is indeed incomplete and
the partial reprogramming of P19 cells mainly results from the
characteristics of the donor nuclei, such as the specific epigenetic
modification patterns, with no direct relationship to the repro-
gramming process itself. Strikingly, the induction of important
genes in EC cells correlates with different regulatory mechanisms,
with H19 in a DMR methylation-dependent pattern and Nanog in
a promoter region methylation-independent pattern. Therefore,
the successful reprogramming of EC cells is still challenging and
further investigation of the regulatory circuits involved in the
reprogramming of EC cells will help us to ultimately conquer this
fundamental question.
Previous attempts at reprogramming tumor cells proved that it
was difficult to reprogram tumor cells or get stable ES cell lines
from cloned blastocysts [14,15,16]. Therefore, tumor cells might
have different attributes that result in the failed reprogramming. It
was reported that EC cells carry many genetic mutations and these
unrecoverable changes may partially explain the failure in the
cloning of EC cells [16]. EC cells have a limited pluripotency, and
they may be easy to reprogram, as suggested by the accumulating
evidence from ES cell cloning and the derivation of iPS cells
[23,24]. We observed that early embryos derived from P19 cells
had a similar developmental rate to those generated from cumulus
cells and ES cell lines could easily be derived from the cloned
blastocysts. Interestingly, one of the derived P19 NTES cell lines
(P19 NTES7) had an improved pluripotency and it could prolong
the development of tetraploid aggregated embryos. We succeeded
in obtaining live E8.5 tetraploid aggregated embryos, which was
our strongest evidence for the improved pluripotency. Compared
to the previous report [16], we employed here tetraploid
complementation assay to evaluate the improved pluripotency of
P19 NTES cells because the previous study used chimera analysis
through which they could not detect obvious improved pluripo-
tency after NT of P19 cells. The improved pluripotency we
observed was verified by the microarray analysis, by which many
biomarkers during this transition process were detected. Although
the improved pluripotency was not sufficient, it was the basis for
the final success in transforming tumor cells into real pluripotent
stem cells.
Recently, new types of pluripotent cells, such as iPS cells and
germline-derived pluripotent stem (gPS) cells have been derived
under specific induction conditions [8,25,26,27,28,29,30]. The
emergence of so many pluripotent cells provided us with models
not only for investigating the occurrence of many regenerative
diseases, but also for investigating the reprogramming mecha-
nisms. Compared to the derivation of iPS and other pluripotent
cells, the ‘‘two-step’’ cloning that relies on the cytoplasm of the
MII oocyte and further in vitro induction could effectively
reprogram cells in a short time. Currently, the mechanism of
reprogramming is still a mystery and we prefer the hypothesis
proposed by Yamanaka [31]. Of note, based on previous work
[17], he hypothesized that the transformation resulting from c-Myc
and Klf4 was followed by a pluripotent cell induction process
regulated by Pou5f1 and Sox2. Recently, the role of Trp53 in the
generation of iPS cells strengthened this hypothesis and the
emergence of cancer-like cells that act as an intermediate may be
indispensable for getting pluripotent iPS cells successfully
[18,32,33,34,35]. Similarly, we found that Trp53 and the members
of P53 signaling pathways were still inactive in EC cell-derived
pluripotent stem cells. In a sense, the repression of the P53
signaling pathway further indicated that EC-derived pluripotent
stem cells had different identities from real pluripotent stem cells.
Meanwhile, the incomplete or failed induction of c-Myc and Klf4
were also observed, which may due to the inactivity of Trp53.E C
cells always had high levels of wildtype P53, which was in a
repressed state modulating by an N-terminal repression domain;
and the repression state would be activated under the induction of
differentiation reagents, such as retinoic acid (RA) [36,37]. As seen
from this, EC cell-derived pluripotent stem cells still carried the
tumorigenic potential and they could escape apoptosis induced by
the Trp53 pathway [38].
The integration of specific signaling pathways into the
definitions of the identities of pluripotent stem cells provided
insights into the features of their transcriptional regulatory
networks [39]. The core of the pluripotency network consisted
of Pou5f1, Sox2 and Nanog, while the LIF-STAT3 and BMP4-ID
pathways could interact with the core members and the final
balanced state among these genes maintained the self-renewal
potential of the pluripotent stem cells [39,40,41,42]. Because the
expression levels of Pou5f1 and Sox2 in the EC cells were
comparable to those of the ES cells, we shifted to study the
Nanog, LIF-STAT3 and BMP4-ID pathways. Intriguingly, we
found that Nanog and BMP4 were both within the differentially
expressed gene set, but not Stat3 or id. Therefore, the core of the
pluripotency network was better-maintained in the P19 cell-
derived pluripotent stem cells, but the external signaling
molecules, such as BMP4, were still somewhat aberrant.
Nevertheless, P19 NTES cells underwent the pluripotency
acquisition process, with Nanog as the typical indication [40].
Nanog has recently been found as the gateway keeper for the
ground-state pluripotency and it played an essential role in the
pluripotency acquisition during the generation of iPS cells and the
conversion of epiblast-derived stem cells (EpiSCs) into ES cells
[43]. Moreover, our results indicate that the induction of Nanog in
P19 NTES cells was promoter region methylation-independent,
which was different from its conventional regulatory mechanism.
In contrast to Nanog, H19 was induced in a DMR methylation-
dependent pattern. H19, a paternally imprinted gene, played an
important role in the developing embryo; and the dysfunction of
H19 always related to many diseases [44,45]. In sum, these data
provide strong evidence that diverse reprogramming mechanisms
worked on different genes. The reprogramming of EC cells may be
a complicated process and the experiences accumulated in this
study may also provide clues for deciphering the reprogramming
mechanisms.
There is increasing evidence that tumor tissues are hierarchi-
cally organized and sustained by a distinct subpopulation of cancer
stem cells (CSCs). CSCs were first isolated from human acute
myeloid leukemia [46], which provided an attractive model for
investigating tumorigenesis. Similar paradigms suggested in solid
tumors were further verified by isolating CSCs from these
transformed tissues [47]. Different CSCs had specific growing
environments, also called ‘‘niches’’, and the properties of CSCs
appeared to be influenced by their specific genetic mutations in a
given tumor tissue as well as the progression of disease [48].
Therefore, the most challenging problem facing this field is the
variability of CSCs coming from their origins. A possible solution
to this challenge would be the identification of an in vitro model of
CSCs. In this study, pluripotent cells were derived from cancer
cells and we named them according to their origins, not their
identities. In order to know their real identities, high-throughput
method was used to find the differences among cancer cells, cancer
cell-derived pluripotent cells and normal ES cells. The final results
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intermediates between cancer cells and ES cells. Although these
intermediates were not fully pluripotent, they still could maintain
the self-renewal ability in vitro and had distinct molecular
characteristics. We predict that when these counterparts of cancer
cells are used in drug screening, they might provide a new path for
obtaining information about killing cancer stem cells.
At the same time, two additional complicated questions remain
to be resolved: What is the difference between pluripotent cells
from cancer cells and CSCs, and what is the hierarchy between
them? It is our hope that our work will pave the way to obtain the
counterpart of CSCs in vitro and perhaps it may help us understand
the occurrence of tumors and the clinical treatment of cancers
more thoroughly.
Materials and Methods
NT and NTES Cell Derivation
Specific pathogen free (SPF) grade mice were housed in the
animal facility of the National Institute of Biological Sciences.
Animal care and handling were conducted in accordance with
policies promulgated by the Ethics Committee of the National
Institute of Biological Sciences.
Metaphase II oocytes were collected from 8- to 10-week-old
female B6D2F1 (C57BL/6 6DBA/2 F1) mice superovulated by
administration of PMSG and hCG. Enucleation and injection
were carried out with a piezo-driven micromanipulator system on
an Olympus X 71 inverted microscopes. Reconstructed oocytes
were activated in 10 mM Sr
2+ in Ca
2+-free medium containing
5 mg/ml cytochalasin B (Sigma, http://www.sigmaaldrich.com/),
and cloned embryos were cultured in KSOM medium (Chemicon,
http://www.chemicon.com/). The establishment of ES cells was
done as previously described [49].
Cell Culture
N2a and P19 cells (ATCC, http://www.atcc.org/) were
cultured in ES medium consisting of DMEM (Chemicon)
supplemented with 15% FBS (Hyclone, http://www.hyclone.
com/), nonessential amino acids (Chemicon), 2-mercaptoethanol
(Chemicon), and 1000 units/ml leukemia inhibitory factor (LIF)
(Chemicon). P19 NTES cells and other kind pluripotent stem cells
were all cultured in ES medium with mouse embryonic fibroblasts
treated with mitomycin C (Sigma) pre-plated on the culture dishes.
Karyotype Analysis
Cells were cultured in ES culture medium containing 0.05 mg/
ml demecolcine (Sigma) for 5 h to arrest cells at M-phase. Then
cells were trypsinized, pelleted by centrifugation and resuspended
in hypotonic solution containing 0.4% NaCl and 0.4% citrate for
5 min. Freshly prepared methanol:acetic acid (3:1) were used to fix
the cells at room temperature for 40 min. Finally, the resuspended
cells were placed onto pre-cleaned slides for chromosomes
counting.
RT-PCR
RT-PCR was performed to investigate the expression of
pluripotency related genes. Trizol (Invitrogen, http://www.
invitrogen.com/) was used to extract total RNA following the
manufacturer’s instructions. Then total RNA was treated with
DNase before reversely transcribing to cDNA using the MLV
reverse transcriptase system (Promega, http://www.promega.com.
cn/). Primer sets for Nanog, Pou5f1, Sox2 and Zfp42 were designed
as previously described [49].
Western Blot
Protein samples were loaded onto 12% SDS-PAGE gel,
resolved and electroblotted onto PVDF membrane. The mem-
brane was blocked in Tris-buffered saline containing 0.1% Tween
20 and 5% low fat dry milk for 1 hour at room temperature.
Then, the PVDF membrane was incubated with diluted primary
antibodies at 4uC overnight. The peroxidase based detection was
performed with Super Signal West Pico Chemiluminescent
Substrate Kits (Pierce, http://www.piercenet.com/). Actin was
used as the inner control.
Rabbit polyclonal anti-Nanog antibody was purchased from
Upstate (Upstate, http://www.chemicon.com/). Rabbit polyclonal
anti-Actin antibody was obtained from Sigma (Sigma).
Teratoma Formation and Tetraploid Blastocyst
Complementation
Teratoma formation was performed to evaluate the in vivo
differentiation capacity of NTES cells. Cells distributed in 200 ml
PBS (Invitrogen) were subcutaneously injected into the forelimb of
SCID-beige mice. Approximately 4 weeks after injection,
teratomas were examined histologically using standard protocols.
Briefly, teratomas were dissected, weighed and fixed in 4%
formaldehyde. The fixed samples were then embedded in paraffin
and tissue sections were stained with hematoxylin and eosin for
analysis (HE).
For the tetraploid aggregated assays, tetraploid blastocysts were
first produced by electrofusion of 2-cell stage embryos of B6D2F1
mice and cultured in KSOM until blastocyst stage [50]. And ES
cells or P19 cells were injected into tetraploid blastocysts using a
piezo-actuated microinjection pipette. Then the tetraploid aggre-
gated embryos were transfer back to KSOM medium for several
hours and transplanted into the uterus of pseudo-pregnant mice.
Real-time PCR
Briefly, Trizol (Invitrogen) was used to extract total RNA. All
the manipulations were according to the manufacturer’s instruc-
tions. Total RNA was treated with DNase (Chemicon) for 30 min,
and then an equal amount of RNA was reverse transcribed to
cDNA using the MLV reverse transcriptase (Promega). Gapdh was
used as the internal control. SYBR green PCR master mix
(TaKaRa, http://www.takara-bio.com/) was employed as the
detector of fluorescence signal, and ABI 7500 was used in
accordance to the manufacturer’s instructions. One independent
experiment contained three replicates of both targeted genes and
inner control. The results of three independent experiments in
duplicate were averaged to get the mean value of every gene.
Paired Student’s t-tests were performed to assess the statistical
difference. The significant standard was set as: fold change .2;
p-value ,0.05. The primer pairs for real-time PCR were
summarized in Table S1.
Bisulfite Genomic Sequencing Analysis of DNA
Methylation
TIANamp Micro DNA Kit (Tiangen, http://www.tiangen.
com/) was used to extract DNA from 1000 tumor cells or ES cells;
and the extracted DNA was treated by EpiTect Bisulfite Kit
(QIAGEN, http://www.qiagen.com/) according to the manufac-
turer’s instructions. Bisulfite modification treatments were tripli-
cated for each sample. Then the treated samples were used as the
template of nest PCR by using Takara Tag HS (TaKaRa). Primer
sets for nest PCR were showed in Table S1. PCR products
were recovered using Wizard SV Gel and PCR Clean-Up
System (Promega). Then the PCR products were cloned into
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PRISM 3100 Genetic Analyzer (Applied BioSystems, http://
www.appliedbiosystems.com/).
Methylation Sensitive Restrictive Enzyme Digestion Assay
of DNA Methylation
Methylation sensitive restrictive enzyme digestion was per-
formed to analyze the methylation profiles of Pou5f1. TaqI (New
England Biolabs, http://www.neb.com/) was used in this assay to
recognize the two sites at the promoter region of Pou5f1. The
digested fragments were electrophoresed on 2.5% agarose gels
containing ethidium bromide.
Microarray Data Processing and Statistical Analysis
In brief, we collected P19 cells and feeder free ES cells from
10 cm diameter culture dish. The collected cells were used for
RNA extraction in Trizol (Invitrogen) reagent. Per sample
contained 3 replicates. GeneChipH Gene 1.0 ST Array System
(http://www.affymetrix.com) was used for microarray assays. For
the data processing and analysis, R/BioConductor was first
performed to analyze the raw data of microarray, and Robust
Multichip Average (RMA) was used for the normalization (scale
median=500). Then, 1-way ANOVA (MATLAB 7.5) (Math-
Works, Inc. http://www.mathworks.com/) was used to identity
the differentially expressed genes. The significance standard was
set as: fold change .2, p-value ,0.01. PCA was also performed to
evaluate the repeatability of every sample.
For the hierarchical clustering analysis of significantly changed
genes, raw signal values were log2-transformed, centered relative
to the median, with the parameters that the distance was a
Euclidean distance and the linkage was the average.
Expression Analysis Systematic Explorer (EASE) was used to
analyze gene ontology and KEGG pathways. Over representation
of genes in a gene ontology node or a KEGG pathway is present if
a larger fraction of genes within that gene ontology node/pathway
is differentially expressed compared with all genes. An EASE
score #0.05 was set as the cutoff [51].
Supporting Information
Table S1 Primer sets for Real-time PCR and nest PCR.
Found at: doi:10.1371/journal.pone.0010320.s001 (0.05 MB
DOC)
Figure S1 Differentially expressed genes of GeneSet B in P53
signaling pathway. Genes in GeneSet B were mapped to the
KEGG signaling pathway database; and the overrepresented
genes were marked in yellow, with the non-corresponding ones
marked in green. p-value , 0.05.
Found at: doi:10.1371/journal.pone.0010320.s002 (1.07 MB TIF)
Figure S2 Differentially expressed genes of GeneSet C in P53
signaling pathway. Genes in GeneSet C were mapped to the
KEGG signaling pathway database; and the overrepresented
genes were marked in blue, with the non-corresponding ones
marked in green. p-value , 0.05.
Found at: doi:10.1371/journal.pone.0010320.s003 (1.07 MB TIF)
Dataset S1 Normalized Microarray Expression Data for
GeneSet A.
Found at: doi:10.1371/journal.pone.0010320.s004 (0.87 MB
XLS)
Dataset S2 Raw data of Real-time PCR for the Verification of
Microarray results.
Found at: doi:10.1371/journal.pone.0010320.s005 (0.03 MB
XLS)
Dataset S3 Normalized Microarray Expression Data for
GeneSet B.
Found at: doi:10.1371/journal.pone.0010320.s006 (0.18 MB
XLS)
Dataset S4 Normalized Microarray Expression Data for
GeneSet C.
Found at: doi:10.1371/journal.pone.0010320.s007 (0.38 MB
XLS)
Dataset S5 Overlapping Analysis Data of GeneSetA, B, C.
Found at: doi:10.1371/journal.pone.0010320.s008 (0.11 MB
XLS)
Dataset S6 Gene Ontology Analysis of Molecular Function.
Found at: doi:10.1371/journal.pone.0010320.s009 (0.03 MB
XLS)
Dataset S7 Gene Ontology Analysis of Biological Process.
Found at: doi:10.1371/journal.pone.0010320.s010 (0.03 MB
XLS)
Dataset S8 Gene Ontology Analysis of Cellular Component.
Found at: doi:10.1371/journal.pone.0010320.s011 (0.03 MB
XLS)
Dataset S9 Pathways Analysis Results of GeneSet A.
Found at: doi:10.1371/journal.pone.0010320.s012 (0.02 MB
XLS)
Dataset S10 Pathways Analysis Results of GeneSet B.
Found at: doi:10.1371/journal.pone.0010320.s013 (0.01 MB
XLS)
Dataset S11 Pathways Analysis Results of GeneSet C.
Found at: doi:10.1371/journal.pone.0010320.s014 (0.01 MB
XLS)
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